Get the Stockscreener App
0.6579
4.21%
-0.0223
Immunic Inc stock is traded at $0.6579, with a volume of 4.80M.
It is down -4.21% in the last 24 hours and down -34.20% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.6801
Open:
$0.7
24h Volume:
4.80M
Relative Volume:
4.76
Market Cap:
$63.04M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3118
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-29.00%
1M Performance:
-34.20%
6M Performance:
-47.46%
1Y Performance:
-46.60%
1-Day Range:
$0.625
$0.735
1-Week Range:
$0.561
$0.95
52-Week Range:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.6579 | 88.22M | 0 | -93.61M | -71.16M | -2.11 |
|
ONC
Beone Medicines Ltd Adr
|
245.81 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.22 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.66 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic (NASDAQ:IMUX) Price Target Lowered to $10.00 at D. Boral Capital - Defense World
Immunic Tumbles After Pricing $65 Million Offering of Warrants - marketscreener.com
Small cap wrap: Fineqia, Synchronoss, Santacruz Silver, Immunic... - Proactive financial news
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Ca - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering | IMUX Stock News - GuruFocus
Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus
Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials - Seeking Alpha
Immunic to raise up to $65M in underwritten public offering - Proactive financial news
Immunic (IMUX) Launches Public Offering with Warrant Options | IMUX Stock News - GuruFocus
Immunic Announces Pricing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus
Immunic Inc. prices $65 million public offering - Investing.com
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Yahoo Finance
Immunic, Inc. Announces Proposed Public Offering - Longview News-Journal
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
Immunic slides on planned equity raise - TradingView
Immunic (IMUX) Launches Public Offering with Pre-Funded and Warr - GuruFocus
Immunic announces public offering of warrants to fund trials - Investing.com India
Immunic Announces Public Offering to Fund Trials - TipRanks
Biotech Immunic Launches Strategic Public Offering to Advance Inflammatory Disease Pipeline - Stock Titan
Immunic's IMU-856 shows promise as Celiac Disease Awareness Month draws to a close - Proactive financial news
Immunic’s (IMUX) Buy Rating Reiterated at B. Riley - Defense World
Analyst Adjusts Target Price for Immunic (IMUX) Amid Strategic F - GuruFocus
Immunic (IMUX) Price Target Lowered by B. Riley Securities | IMU - GuruFocus
Analyst Adjusts Target Price for Immunic (IMUX) Amid Strategic Financing Prospects | IMUX Stock News - GuruFocus
B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating - marketscreener.com
Janus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $13.20 Average Price Target from Analysts - Defense World
Immunic: Q1 Earnings Snapshot - CT Insider
Barclays PLC Takes $84,000 Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic (IMUX) Projected to Post Earnings on Wednesday - Defense World
Immunic CMO on Celiac Disease Awareness Month, potential of IMU-856 - Proactive financial news
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial - Proactive financial news
36,811 Shares in Immunic, Inc. (NASDAQ:IMUX) Acquired by Invesco Ltd. - Defense World
Immunic (IMUX) Stock Price, News & Analysis - MarketBeat
Where Do Analysts See Immunic Inc (NASDAQ: IMUX) Heading? - Stocksregister
Renaissance Technologies LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital - Defense World
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
IMUXImmunic Inc Latest Stock News & Market Updates - Stock Titan
Immunic to Participate in Scientific and Industry Conferences in May | IMUX Stock News - GuruFocus
Immunic to Participate in Scientific and Industry Conferences in May - The Malaysian Reserve
Immunic Reveals New Clinical Data for Celiac Disease and MS Drugs at Three Major Medical Conferences - Stock Titan
Immunic presses ahead with MS drug despite Phase II endpoint miss - Yahoo
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Pr - GuruFocus
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Price Target | IMUX Stock News - GuruFocus
What is Immunic Inc (IMUX) Stock Return on Shareholders’ Capital? - Sete News
Daily Progress: Immunic Inc (IMUX) Drop -22.65, Closing at 0.99 - DWinneX
MS drug shows promise in progressive cases, despite missed trial goal - The Pharma Letter
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):